Patents Represented by Attorney Kalow & Springut LLP

Find this attorney in the Justia Lawyer Directory

  • siRNA targeting DNA-damage-inducible transcript 4 (DDIT4)
    Patent number: 7655788
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to DDIT4.
    Type: Grant
    Filed: July 24, 2007
    Date of Patent: February 2, 2010
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting transient receptor potential cation channel, subfamily V, member 1 (TRPV1)
    Patent number: 7655789
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TRPV1.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: February 2, 2010
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting spleen tyrosine kinase
    Patent number: 7645869
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.
    Type: Grant
    Filed: December 4, 2006
    Date of Patent: January 12, 2010
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Stephen Scaringe, Steven Read
  • siRNA targeting proteasome 26S subunit, non-ATPase, 10 (Gankyrin or PSMD10)
    Patent number: 7645870
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to PSMD10.
    Type: Grant
    Filed: June 8, 2007
    Date of Patent: January 12, 2010
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting TATA box binding protein (TBP)-associated factor (TAF1)
    Patent number: 7642349
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TAF1.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: January 5, 2010
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting insulin-like growth factor 1 receptor (IGF-1R)
    Patent number: 7638621
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to Insulin-Like Growth Factor 1 Receptor (IGF-1R).
    Type: Grant
    Filed: April 3, 2007
    Date of Patent: December 29, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • SiRNA targeting intercellular adhesion molecule 1 (ICAM1)
    Patent number: 7638622
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for ICAM1.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: December 29, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting protein kinase N-3 (PKN-3)
    Patent number: 7635770
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to PKN-3.
    Type: Grant
    Filed: July 24, 2007
    Date of Patent: December 22, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting amyloid beta (A4) precursor protein (APP)
    Patent number: 7635771
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APP.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: December 22, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting superoxide dismutase 1 (SOD1)
    Patent number: 7632938
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for SOD1.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: December 15, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting proto-oncogene MET
    Patent number: 7632939
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for proto-oncogene MET.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: December 15, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Glycerophosphoinositol derivatives as modulators of cytosolic A2 phospholipase
    Patent number: 7625883
    Abstract: Optionally O-substituted glycero-phosphoinositol derivatives, their analogues and their salts wherein the substitutents: R?1, R?2, R2, R3, R4, R5, R6 have the described meaning, their synthesis and their pharmacological effect as modulators of the activation or over-stimulation of cPLA2.
    Type: Grant
    Filed: November 7, 2000
    Date of Patent: December 1, 2009
    Assignee: I.R.B. Istituto di Ricerche Biotechnologiche S.R.L.
    Inventors: Daniela Corda, Roberto Dal Toso, Giovanna Bonvento, Gabriele Marcolongo, Renzo Dal Monte
  • siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
    Patent number: 7619081
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to COPB2.
    Type: Grant
    Filed: May 30, 2007
    Date of Patent: November 17, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Link
    Patent number: D603749
    Type: Grant
    Filed: October 7, 2008
    Date of Patent: November 10, 2009
    Assignee: Cartier Creation Studio SA
    Inventors: Nathalie Verdeille, Swan Lucia Kim
  • Docking station
    Patent number: D604721
    Type: Grant
    Filed: October 28, 2008
    Date of Patent: November 24, 2009
    Assignee: Coby Electronics Corporation
    Inventor: Johann Lee
  • Docking station
    Patent number: D606044
    Type: Grant
    Filed: September 25, 2008
    Date of Patent: December 15, 2009
    Assignee: Coby Electronics Corporation
    Inventor: Johann Lee
  • Ring
    Patent number: D606895
    Type: Grant
    Filed: June 15, 2009
    Date of Patent: December 29, 2009
    Assignee: Cartier Creation Studio SA
    Inventor: Wilfrid Lebail
  • Perfume bottle
    Patent number: D608646
    Type: Grant
    Filed: April 10, 2008
    Date of Patent: January 26, 2010
    Assignee: Cartier Creation Studio SA
    Inventor: Damienne Lulic
  • Watch dial
    Patent number: D608675
    Type: Grant
    Filed: October 2, 2008
    Date of Patent: January 26, 2010
    Assignee: Cartier Creation Studio SA
    Inventor: Serge Rabassa
  • Gown
    Patent number: D608980
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: February 2, 2010
    Assignee: The New York Hospital Medical Center of Queens
    Inventor: Terence Michael Brady